Tags: Lilly | Drop | Profit | drug

Lilly Projects Sharp Drop in 2012 Profit

Thursday, 05 Jan 2012 08:26 AM

Eli Lilly & Co. forecast a steeper-than-expected decline in profit for 2012, the first full year without exclusive rights to its big-selling Zyprexa schizophrenia treatment.

Shares fell 3.5 percent after Lilly announced its forecast on Thursday.

The drugmaker projected earnings in the range of $3.10 per share to $3.20 per share for 2012. For 2011, Lilly said it expects to meet or exceed its profit forecast of $4.30 per share to $4.35 per share, excluding items. Including items, Lilly sees 2011 earnings per share of $3.84 to $3.89.

Analysts were looking for $3.61 per share in 2012, according to Thomson Reuters I/B/E/S.

Zyprexa, a $4.5 billion-a-year product, began facing competition in October from low-cost generic versions in the United States.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
120
2012-26-05
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved